Background: Febrile neutropenia (FN), a decrease in blood neutrophils accompanied by fever, is a major adverse event (AE) associated with cancer chemotherapy. We aimed to estimate the direct medical costs associated with FN management in breast cancer patients within a clinical trial with pegfilgrastim, a pegylated form of recombinant granulocyte colony-stimulating factor (G-CSF). Methods: We obtained data from 346 Japanese breast cancer patients in a randomized, placebocontrolled clinical trial comparing FN incidence due to TC adjuvant chemotherapy (docetaxel 75 mg/m 2 , cyclophosphamide 600 mg/m
Background
Neutropenia is a principal dose-limiting toxic side effect of cancer chemotherapy. Neutropenia with fever, febrile neutropenia (FN), is a serious complication of chemotherapy that often requires hospitalization and medical management (1) . Once FN occurs, chemotherapy cannot continue as planned and clinicians must consider dose reduction or treatment delay. Prophylactic treatment with granulocyte colony-stimulating factor (G-CSF) provides protection for patients at risk of FN and thus obviates dose reductions or delays that can reduce anti-cancer efficacy. Indeed, a retrospective study of anthracycline-based adjuvant chemotherapy for early-stage breast cancer showed that a relative dose intensity (RDI) of chemotherapy ≥ 85% of the planned dose was associated with longer disease-free and overall survival compared to RDI < 85% (2) . In addition, previous retrospective studies of early-stage breast cancer patients found that primary prophylaxis with G-CSF (PPG-CSF) was associated with decreased risk of dose reduction (3, 4) . Guidelines from the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the European Organisation for Research and Treatment of Cancer (EORTC) recommend the use of PPG-CSF for patients whose overall risk of FN exceeds 20% and in cases where dose reduction may compromise the efficacy of the chemotherapy used for curative intent (5-7).
Although taxane-based chemotherapy regimens such as TAC (docetaxel [DTX]/doxorubicin [ADM]/cyclophosphamide [CPA] ) and dose-dense AC-T (ADM/CPA followed by paclitaxel [PTX] ) are known for their myelosuppressive toxicity and concomitant risk of FN, these regimens improve the overall survival of breast cancer patients (8, 9) . Thus, FN prophylaxis is a critical component of optimal cancer treatment. However, as PPG-CSF has not been approved for breast cancer patients in Japan (10) , the dose and intensity of chemotherapeutic agents are often lower than recommended based on clinical studies (8, 9) . In addition, recent studies suggest that Japanese and other Asian populations are at greater risk of serious complications, including FN, associated with taxane-based chemotherapy (11) (12) (13) . In a randomized placebo-controlled Phase III clinical trial in Japanese breast cancer patients (Registration No.: JAPIC CTI-111446), pegfilgrastim, a long-acting form of G-CSF (filgrastim), reduced the incidence of FN from 119/173 (68.8%) in the placebo group to 2/173 (1.2%) in the pegfilgrastim group (14) .
The high cost of managing complications associated with chemotherapy such as FN is a significant economic concern for the health insurance system. Following inclusion of PPG-CSF for FN in the first guidelines by ASCO in 1994 (15), several cost-effectiveness studies evaluating PPG-CSF for FN were conducted in Europe and the United States (US) (16, 17) . Despite the need for economic evaluation of treatments for breast cancer in Japan (18, 19) , the medical costs associated with FN treatment in Japan remain unknown (20, 21) .
Here, we evaluated the medical costs associated with FN treatment during chemotherapy using data from a Japanese clinical trial of pegfilgrastim.
Materials
Patients, study design and settings Using data from a randomized placebo-controlled Phase III clinical trial of pegfilgrastim (Registration No.: JAPIC CTI-111446), we analyzed costs associated with adjuvant chemotherapy and adverse events (AEs), including FN. All patient data remained anonymous.
The protocol of this study was approved by the ethics committee of Kyoto University Graduate School of Medicine.
The clinical trial assessed the efficacy and safety of prophylactic pegfilgrastim for the FN prevention in early-stage breast cancer patients (14) . Three hundred fifty-one (177 in pegfilgrastim group and 174 in placebo) women between 20 and 69 years of age with Stage I-III invasive breast carcinoma who were to receive TC chemotherapy (docetaxel 75 mg/m 2 and cyclophosphamide 600 mg/ m 2 every 3 weeks) as either neoadjuvant or adjuvant therapy were enrolled and 346 subjects were treated with either pegfilgrastim (n = 173) or placebo (n = 173). Pegfilgrastim 3.6 mg or placebo was administered once per chemotherapy cycle to primary breast cancer patients receiving four or six cycles of TC chemotherapy. The dosage of pegfilgrastim was based on the dose-response curve from a multi-dose Phase II clinical trial in Japan (22) . Patients who experienced protocol-defined FN during chemotherapy were moved to an unblinded treatment group in which they received the same treatment as the pegfilgrastim group. Unlike general cost analysis, we calculated all medical costs based on data which were recorded in accordance with the specified schedule for observation on this clinical trial (as showed in Supplemental File 3). Other details of the trial design and characteristics of the trial subjects were reported by Kosaka et al. (14) .
Methods

Data source and cost calculations
Data for this cost analysis were obtained without compromising patient anonymity. Data gathered included patient demographics, chemotherapy regimens and all AE treatments (drugs and hospitalizations). In our estimation of costs, a cost of therapeutic G-CSF use was calculated separately from that of prophylactic pegfilgrastim use. Data on other procedures such as administration of drugs, laboratory examinations and imaging were not available. Therefore, costs of these procedures were not considered except for a hospitalization cost that could be estimated based on the DPC payment fee in the National Health Insurance (NHI) system as described later. Drug costs were calculated from 4200 records of concomitant drugs for AE management in the clinical trial, excluding 15 records for drugs not reimbursed by health insurance, such as vaccines. We first extracted drug name (brand or generic), route of administration and dosing days from the prescribed drug data for each medication. To avoid over-estimating the economic impact of prophylactic pegfilgrastim use on FN treatment costs, even in cases where a drug name was specified, we conservatively chose the cheapest drug for cost estimates to ensure a minimum daily cost still consistent with the prescription, and wherever possible chose generic drugs included in the NHI drug price list (as of December 2013). The cost of pegfilgrastim was derived from the official drug price (as of November 2014). For some topical drugs, such as ophthalmic drugs, doses were determined as once a day with the cheapest drug or combination of drugs regardless of dosing days. For the dosing period of concomitant drugs, we used the observation period specified in the Phase III clinical trial protocol, although actual dosing days might have been longer than the observation period.
In FN treatment, hospitalization could be assumed to occupy the medical cost, so, in our study, we chosen the complementary estimation method using Diagnosis Procedure Combination (DPC)/perdiem payment system for the total medical cost of hospitalization related to FN treatment based on the relevant data from the clinical trial. Costs for all medical procedures during hospitalization other than basic hospitalization costs were estimated according to the DPC System of the Japanese NHI system in 2012 (23) because detailed cost data for treatments and procedures during hospitalization due to AE were not collected in the clinical trial. Hospitalization costs were calculated using the following formula and referring to the DPC classification for each hospitalization case:
Total DPC Payment Fixed score per day for DPC code Coefficent for hospital Length of stay 10
The code for hospitalization due to FN was determined from the major diagnosis class (MDC) of white blood cell disorders (MDC 130070) and that of hospitalizations due to other AEs related to breast cancer treatment (MDC 090010) by consultation with the expert in payment from the administrative office of Kyoto University Hospital. The coefficient for hospital set by the Ministry of Health, Labour and Welfare for Kyoto University Hospital was 1.4543 in 2012. Length of stay (LOS) was derived from the actual data recorded for each AE during the clinical trial.
Statistical analysis
Cost analysis in both the pegfilgrastim group and placebo group was performed for the ITT population. Statistical tests included Wilcoxon test, with P < 0.05 considered statistically significant. We compared the costs of chemotherapy, concomitant drugs, and hospitalization for all AE treatments, as well as costs for FN treatment only in the entire group (mean cost per patient for all patients in the clinical trial). The costs associated with FN management were also analyzed in those patients that actually developed FN. As 111 patients in the placebo group (64.2%) were moved to the unblinded treatment phase due to FN (24) , main analyses were conducted for the first cycle in order to maintain internal validity in comparisons between treatment groups. The sponsor company had previously classified concomitant drugs, so we also applied this classification for the current analysis. As sensitivity analysis, we indicated the result considering cost of brand-name drugs as well (Supplemental File 4).
Results
The total cost during the first cycle of chemotherapy was ¥189 135 in the pegfilgrastim group and ¥98 106 in the placebo group. 56.4% of the total cost in the intervention group was derived from the prophylactic use of pegfilgrastim. AEs occurred in all patients, but most were expected from the chemotherapy regimen, and none were severe enough to result in death. The drug cost for all AE treatments in the corresponding group was ¥7805 and ¥14 411, respectively ( Table 1) . Analysis of the proportion of the total AE drug cost expended on each drug class revealed that antiemetics were the greatest expense in the pegfilgrastim group and that antiemetics and G-CSFs were the greatest expenses in the placebo group (Fig. 1) . Hospitalization cost associated with each AE was estimated by subtracting the concomitant drug cost for AE treatment during hospitalization from the reimbursement fee in the Diagnosis Procedure Combination (DPC)-based payment system for each patient. The total cost of antiemetics did not differ significantly between the groups, but the total cost of therapeutic G-CSF use was significantly higher in the placebo group, especially during the first cycle, due to the higher incidence of FN. With the exception of antibiotics and G-CSFs, all mean drug costs were similar between the two groups (Supplemental File 1).
In the clinical trial, 25 patients in the placebo group were hospitalized due to AEs (mean LOS: 6.8 days), including 12 with FN (mean LOS: 6.6 days), whereas no patients in the pegfilgrastim group required FN-related hospitalization. The estimated mean hospitalization cost for the pegfilgrastim group in the first cycle was ¥2425, costs substantially lower than in the placebo group at ¥11 180 ( Table 1) .
The estimated drug cost of FN treatment for the placebo group was ¥6453 and cost of hospitalization due to FN was ¥16 429. The largest proportion of the drug cost related to FN treatment was G-CSF with therapeutic use (Supplemental File 2).
Mean drug cost for patients who developed and were treated for FN during the first cycle (n = 100) was ¥11 145 compared to only ¥27 for placebo group patients who did not develop FN (n = 73) ( Table 2 ). The cost associated with FN treatment including hospitalization was ¥27 in patients without FN and ¥28 420 in patients with FN. In addition, a sensitivity analysis using brand name drug for all the medication cost indicated that there was no any change in the results (Supplemental File 4).
Discussion
In this study, we surveyed drug and hospitalization costs associated with treatment of all AEs, including FN, caused by TC therapy as adjuvant chemotherapy for the treatment of breast cancer in a clinical trial of pegfilgrastim. When we estimate the total medical costs including prophylactic agents and hospitalization, in the first cycle of chemotherapy based on Tables 1 and 3 , the cost for pegfilgrastim groups was at least ¥90 000 higher but the medical cost limited to FN treatment was ¥16 000 lower than the placebo group. This cost reduction is due to the dramatic decrease in FN incidence under pegfilgrastim prophylaxis.
Moreover, in the estimation of medication costs, we intentionally chose generic drugs as much as possible. Thereby, we concerned underestimate of those costs, but a sensitivity analysis using the price of brandname drugs also demonstrated similar results (Supplemental File 4).
Regarding the cost related to AE treatment, hospitalization costs accounted for 60% of the difference between the groups, whereas G-CSF and antibiotics accounted for most of the remaining medical costs. Although the routine therapeutic use of G-CSF for FN is not recommended by current Japanese clinical guidelines due to a lack of evidence for infection-related mortality, the treatment use of G-CSF was permitted for patients with FN in this clinical trial (5-7).
Our analysis has several limitations. First, it was based on patient data from a randomized clinical trial of pegfilgrastim and so may not represent the general patient population treated in clinical practice. The cost of concomitant drugs associated with FN treatment may be less generalizable since FN prophylaxis with G-CSF had not been used for breast cancer in Japan. And, after the end of the first cycle of chemotherapy, 111 patients (63.8%) in total of the placebo group and one patient (0.6%) of pegfilgrastim group were permitted to receive open-label pegfilgrastim treatment after experiencing FN, it might have affected a certain level in direction of underestimation. And, after the end of the first cycle of chemotherapy, 111 patients (63.8%) in total of the placebo group were permitted to receive openlabel pegfilgrastim treatment after experiencing FN, it might have affected a certain level in direction of underestimation. Second, since the design of the clinical trial was not aimed at cost analysis, some of the relevant information for our study, such as dosages of concomitant drugs and actual indication of prescribed drugs, was not available. All the data have been recorded according to the study protocol (Supplemental File 3), therefore these are assumption and do not necessarily reflect the actual claim-data written based on medical records. Thirdly, all medication costs were conservatively estimated by substituting the lowest dose and price of each drug because of lack Figure 1 . Drug costs associated with all AE treatments by drug class. The cumulative monetary value in Japanese Yen (JPY¥) of concomitant drugs related to all AE treatments in the first chemotherapy cycle (left) and all cycles (right) (based on ITT population analysis). AE, adverse event; NSAIDs, non-steroidal antiinflammatory drugs; G-CSF, granulocyte colony-stimulating factor; ITT, intent-to-treat.
of information on the brand name of drugs. Furthermore, the price of each drug was derived from the NHI price list in 2014. However, given the relatively low market share of generic drugs in Japan at that time of this analysis (i.e., 30%) (25) , the FN management costs estimated in this study are expected to be lower than the actual costs only slightly.
In our study, the cost related to FN management per patient in the first cycle was~¥28 000 and the total medical cost including pegfilgrastim with secondary prophylaxis for FN in the subsequent cycle was around ¥320 000. A recent study in the United States indicated that the mean cost of FN treatment including G-CSF was US $1094 (¥120.340, 1USD = ¥110 as of 2017) for outpatients and US $10 354 (¥1139) for hospitalized patients (26) . However, they did not report the formulation of G-CSF as well as the patient ratio that prophylactic G-CSF was used. Therefore, the total cost of FN treatment would still be lower in comparison with the US, when the cost of prophylactic pegfilgrastim was excluded from the FN management costs in the US. We speculate that the reason for the lower cost is the different use and dosage of G-CSF in Japan compared with the US. Unlike the US and many other countries, the prophylactic use of G-CSF for breast cancer patients had not been approved in Japan (except for pegfilgrastim), and the approved dosage of G-CSF for FN is lower. In contrast, criteria for chemotherapy and usage of antibiotics for FN treatment are similar in relevant US and Japanese clinical guidelines (27, 28) . The present results are consistent with the findings of a previous study showing lower treatment costs for breast cancer treatment in Japan compared with other countries (20) . Breast cancer patients who developed severe FN due to suspected infection during outpatient chemotherapy require daily oral antibiotics as outpatient for low risk patient. Others require daily injections of antibiotics which necessitate hospitalization. In contrast, pegfilgrastim is administered only once per chemotherapy cycle for prophylactic use and indeed, this treatment substantially reduced FN incidence. Prophylactic use of pegfilgrastim could therefore reduce unplanned outpatient visits and hospitalization during chemotherapy. For most patients, outpatient chemotherapy is thought to reduce medical costs and improve quality of life (QOL) (29) . In addition, the prophylactic use of pegfilgrastim may contribute to the completion of chemotherapy regimens with high FN frequency such as TAC and dose-dense AC-T. This could in turn prolong the survival of breast cancer patients. Therefore, PPG-CSF at the recommended dose (3.6 mg/cycle) for FN prevention may reduce health care expenditures by facilitating outpatient chemotherapy and affording long-term clinical benefits, resulting in more cost-effective treatment (22) .
Compared to the placebo group without a prophylactic pegfilgrastim in the clinical trial, the total medical costs of the pegfilgrastim group was considerably higher. Therefore, appropriate model for evaluating the cost-effectiveness of pegfilgrastim as primary prophylaxis in the long-term treatment of breast cancer patients should include factors such as cost, QOL, dose intensity and patient survival. Our results provide useful information related to the cost of FN treatment for such studies.
Conclusions
Pegfilgrastim for prevention of chemotherapy-induced FN reduced the costs incurred for both AE drugs and hospitalization for AEs, although the total medical cost during the first cycle of chemotherapy increased. Our study constitutes baseline data for further health economic evaluations of pegfilgrastim.
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